Liver transplantation and hepatocellular carcinoma 2023: a narrative review of management and outcomes.

Autor:	Tabrizian P; Mount Sinai Medical Center, Recanati/Miller Transplantation Institute, Transplantation, New York, NY, USA., Holzner ML; Mount Sinai Medical Center, Recanati/Miller Transplantation Institute, Transplantation, New York, NY, USA., Zaret D; Mount Sinai Medical Center, Recanati/Miller Transplantation Institute, Transplantation, New York, NY, USA., Meyerovich G; Mount Sinai Medical Center, Recanati/Miller Transplantation Institute, Transplantation, New York, NY, USA., Fagenson A; Mount Sinai Medical Center, Recanati/Miller Transplantation Institute, Transplantation, New York, NY, USA., Schiano T; Mount Sinai Medical Center, Recanati/Miller Transplantation Institute, Transplantation, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Annals of palliative medicine [Ann Palliat Med] 2024 Jan; Vol. 13 (1), pp. 126-140. Date of Electronic Publication: 2023 Dec 18.
DOI:	10.21037/apm-23-341
Abstrakt:	Background and Objective: Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality in the United States. For certain patients, liver transplantation (LT) may be curative. The determination of which patients would benefit most from transplant and have the lowest risk of post-transplant recurrence has evolved as technology and treatments have expanded. We aim to review epidemiological changes in the HCC landscape, selection criteria for transplant, organ allocation, bridge therapies and post-transplant recurrence, and identify points for palliative care involvement. Methods: Literature review was performed using PubMed MeSH searches in addition to reference list review. Additional information was retrieved from government regulatory and procurement organizations. Key Content and Findings: Metabolic and alcohol-associated liver diseases have surpassed hepatitis C as the leading causes of LT over the last decade, and have also risen as the underlying conditions seen in patients with HCC requiring LT. The United Network for Organ Sharing (UNOS) coordinates organ allocation, which includes disease severity, waitlist time, blood type, and distance from donor hospital. It has progressed to incorporate treatment response and alpha-fetoprotein into its listing criteria for patients with HCC, in addition to the well-established Milan Criteria (MC, one tumor <5 cm, ≤3 tumors ≤3 cm). Therapies to bridge patients until LT include locoregional therapies as well as immunotherapy. Dropout on the waitlist is seen up to 20% either due to decompensation or progression of disease. Recurrence of HCC post-transplant remains challenging. Given this, current guidelines recommend early palliative care involvement regardless of transplant listing status for both symptom management and advance care planning. Conclusions: For patients with HCC with favorable tumor biology, LT can be curative. However, given the symptom burden while awaiting LT and the notable number of patients who are unable to receive a transplant, early palliative care is critical in appropriate management of HCC.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu